HanAll Biopharma and Daewoong Entered into Co-Development Agreement with NurrOn to Develop Novel Therapies for Parkinson's Disease
Shots:
- The companies collaborated to discover & develop novel therapies for patients with neurodegenerative diseases incl. Parkinson's disease
- The collaboration will combine companies’ expertise and resources in developing NurrOn's ATH-399A & other compounds targeting Nurr1 for neurodegenerative disorders. The P-I trial of ATH-399A is expected to be initiated in 2023
- The companies also continue to advance the therapy in other neurodegenerative diseases. HanAll’s HL161, an anti-FcRn Ab is being evaluated in P-II & P-III trials for autoimmune diseases incl. MG, TED, CIDP, and GD while HL036, a TNF-alpha inhibitor protein is being studied in the P-III trials in the US & China for dry eye disease
Ref: PR Newswire | Image: Hanall
Related News:- Akebia Signs a License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG to Commercialize Vafseo for Anemia Associated with CKD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
